eNOS gene therapy (Valentis/Ark Therapeutics)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameeNOS gene therapy (Valentis/Ark Therapeutics)
Drug Alias Namerestenosis gene therapy (Valentis/Ark Therapeutics)
ClassificationCell and gene therapy > Gene therapy
Mechanisms of ActionNitric oxide synthesis stimulants
TargetsUpdating
Therapy Area/IndicationsCoronary Restenosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesStanford University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPremier Veterinary Group PlcValentis
Active IndicationsN/A
Inactive IndicationsCoronary Restenosis

Other Information

ATC CodeN/A
Related LinksN/A